BR112021026916A2 - Métodos de tratamento de hiv em pacientes pediátricos com rilpivirina - Google Patents

Métodos de tratamento de hiv em pacientes pediátricos com rilpivirina

Info

Publication number
BR112021026916A2
BR112021026916A2 BR112021026916A BR112021026916A BR112021026916A2 BR 112021026916 A2 BR112021026916 A2 BR 112021026916A2 BR 112021026916 A BR112021026916 A BR 112021026916A BR 112021026916 A BR112021026916 A BR 112021026916A BR 112021026916 A2 BR112021026916 A2 BR 112021026916A2
Authority
BR
Brazil
Prior art keywords
rilpivirine
methods
pediatric patients
treating hiv
pediatric
Prior art date
Application number
BR112021026916A
Other languages
English (en)
Portuguese (pt)
Inventor
Herta Crauwels
Simon Vanveggel
VAN EYGEN Veerle
Original Assignee
Janssen Sciences Ireland Unlimited Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Sciences Ireland Unlimited Co filed Critical Janssen Sciences Ireland Unlimited Co
Publication of BR112021026916A2 publication Critical patent/BR112021026916A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
BR112021026916A 2019-07-03 2020-07-02 Métodos de tratamento de hiv em pacientes pediátricos com rilpivirina BR112021026916A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962870413P 2019-07-03 2019-07-03
PCT/EP2020/068734 WO2021001508A1 (en) 2019-07-03 2020-07-02 Methods of treating hiv in pediatric patients with rilpivirine

Publications (1)

Publication Number Publication Date
BR112021026916A2 true BR112021026916A2 (pt) 2022-05-10

Family

ID=71579550

Family Applications (2)

Application Number Title Priority Date Filing Date
BR112021026916A BR112021026916A2 (pt) 2019-07-03 2020-07-02 Métodos de tratamento de hiv em pacientes pediátricos com rilpivirina
BR112021026739A BR112021026739A2 (pt) 2019-07-03 2020-07-03 Métodos de tratamento de hiv em pacientes pediátricos com rilpivirina

Family Applications After (1)

Application Number Title Priority Date Filing Date
BR112021026739A BR112021026739A2 (pt) 2019-07-03 2020-07-03 Métodos de tratamento de hiv em pacientes pediátricos com rilpivirina

Country Status (14)

Country Link
US (3) US20210000823A1 (cg-RX-API-DMAC7.html)
EP (2) EP3993799A1 (cg-RX-API-DMAC7.html)
JP (4) JP2022538338A (cg-RX-API-DMAC7.html)
KR (2) KR20220028049A (cg-RX-API-DMAC7.html)
CN (2) CN114126655A (cg-RX-API-DMAC7.html)
AU (2) AU2020300818A1 (cg-RX-API-DMAC7.html)
BR (2) BR112021026916A2 (cg-RX-API-DMAC7.html)
CA (1) CA3144307A1 (cg-RX-API-DMAC7.html)
IL (1) IL289457A (cg-RX-API-DMAC7.html)
JO (1) JOP20210347A1 (cg-RX-API-DMAC7.html)
MA (2) MA56449A (cg-RX-API-DMAC7.html)
MX (2) MX2022000060A (cg-RX-API-DMAC7.html)
PH (1) PH12021553288A1 (cg-RX-API-DMAC7.html)
WO (2) WO2021001508A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA56449A (fr) * 2019-07-03 2022-05-11 Janssen Sciences Ireland Unlimited Co Procédés de traitement du vih chez des patients pédiatriques par la rilpivirine

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3429B1 (ar) * 2001-08-13 2019-10-20 Janssen Pharmaceutica Nv مشتقات برميدينات مثبطة فيروس الايدز
AR065720A1 (es) * 2007-03-14 2009-06-24 Tibotec Pharm Ltd Polvos para reconstitucion que comprenden rilpivirina dispersos en ciertos polimeros. uso. proceso.
NZ610729A (en) * 2010-11-19 2015-10-30 Gilead Sciences Inc Therapeutic compositions comprising rilpivirine hcl and tenofovir disoproxil fumarate
CA2921336A1 (en) * 2015-06-30 2016-12-30 Gilead Sciences, Inc. Pharmaceutical formulations
EP4233846B1 (en) * 2015-06-30 2024-12-04 Gilead Sciences, Inc. Pharmaceutical formulations
MA46563B1 (fr) * 2016-10-24 2024-01-31 Janssen Sciences Ireland Unlimited Co Compositions dispersibles
RU2755710C2 (ru) * 2017-06-30 2021-09-20 Вайв Хелткер Компани Комбинация, ее применение и способы лечения с использованием указанной комбинации
MA56449A (fr) * 2019-07-03 2022-05-11 Janssen Sciences Ireland Unlimited Co Procédés de traitement du vih chez des patients pédiatriques par la rilpivirine

Also Published As

Publication number Publication date
WO2021001568A1 (en) 2021-01-07
MA56449A (fr) 2022-05-11
MX2021015627A (es) 2022-04-25
CN114126655A (zh) 2022-03-01
JP2026097814A (ja) 2026-06-16
CN114080223A (zh) 2022-02-22
CA3144307A1 (en) 2021-01-07
EP3993799A1 (en) 2022-05-11
JP2022538449A (ja) 2022-09-02
JP2022538338A (ja) 2022-09-01
MX2022000060A (es) 2022-04-18
JP2026097815A (ja) 2026-06-16
KR20220028048A (ko) 2022-03-08
US20220313693A1 (en) 2022-10-06
CA3144534A1 (en) 2021-01-07
KR20220028049A (ko) 2022-03-08
AU2020300818A1 (en) 2022-03-03
BR112021026739A2 (pt) 2022-04-26
EP3993800A1 (en) 2022-05-11
US20240139186A1 (en) 2024-05-02
PH12021553288A1 (en) 2022-08-01
US20210000823A1 (en) 2021-01-07
WO2021001508A1 (en) 2021-01-07
IL289457A (en) 2022-02-01
MA56453A (fr) 2022-05-11
JOP20210347A1 (ar) 2023-01-30
AU2020300033A1 (en) 2022-02-24

Similar Documents

Publication Publication Date Title
BR112018070017A2 (pt) métodos de tratamento de cânceres pediátricos
EP4477662A3 (en) Nucleic acid molecules and uses thereof
BR112018016341A2 (pt) solução de bloqueio do cateter e terapia de bloqueio do cateter
EA202191133A1 (ru) Сигнатуры интерферона типа i и способы их применения
BR112018069776A2 (pt) tratamento de psoríase com intervalo de dosagem aumentado de anticorpos anti-il-12 e/ou anti-il-23
BR112019005944A2 (pt) anticorpos que se ligam à interleucina 2 e usos dos mesmos
MX390722B (es) Tratamiento de resistencia a diureticos.
ZA202300222B (en) Anti-αlpha-4-βeta-7 antibodies
CL2016002827A1 (es) Sistema para limpiar una región ocular, que comprende a un aplicardor que consiste de una primera y segunda camara, un elemento sellable que divide la primera y segunda camara, donde la segunda camara contiene una composicion ocular y b un surtidor kit y metodos de tratamientos.
BR112016016880A2 (pt) Combinação para tratar câncer e seu uso, kit, e composição farmacêutica
BR112019005539A2 (pt) métodos de tratamento de lesão renal aguda
MY202382A (en) Obinutuzumab treatment of a dlbcl patient subgroup
MX2021015448A (es) Células linfocíticas activadas y métodos para usarlas para tratar cáncer y afecciones infecciosas.
PH12022552499A1 (en) Technologies for preventing or treating infections
PH12015501574A1 (en) Diposable diaper
BR102018068947A8 (pt) sistemas de instrumento cirúrgico ortopédico específicos para um lado do corpo e métodos de uso associados
BR112021020962A2 (pt) Métodos de tratamento de prurido
BR112021026739A2 (pt) Métodos de tratamento de hiv em pacientes pediátricos com rilpivirina
BR112021005759A2 (pt) composto, medicamento, métodos de modulação alostérica positiva e para a profilaxia ou o tratamento de constipação, e, uso do composto ou de um sal do mesmo
CO2025004675A2 (es) Método para tratar vih con cabotegravir y rilpivirina en pacientes pediátricos
BR112022026126A2 (pt) Formulações
BR112019004838A2 (pt) tratamento de linfoma não-hodgkin usando lilotomab e 177lu-lilotomab satetraxetan
EA201891922A1 (ru) Лекарственное средство для лечения инфекций на фоне диабетической стопы
MX394902B (es) Secuelas de lesión pulmonar inducida por baipás cardiopulmonar.
MX2020002485A (es) Metodos de uso del dantroleno para tratar la exposicion a agente nervioso.

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A ANUIDADE.